FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2602247476> ?p ?o ?g. }

• W2602247476 abstract "e11615 Background: Gene expression studies have demonstrated that breast cancer can be divided into three major subgroups : Luminal, Human Epidermal Growth Factor Receptor-2 (HER2) over-expression and Oestrogen negative (ER-). Luminal breast cancer is well known for its better prognosis compared with the other types. Conversely, response is less effective by pCR criteria after chemotherapy. This work aimed to evaluate if pCR could still be considered as a surrogate marker in luminal subgroup according to immunohistochemical classification : Hormonal receptor positive and HER2 negative (HR+HER2-). Methods: All 132 luminal early breast cancer patients treated by neo-adjuvant chemotherapy (NAC), in our institution from 2001 to 2007 were included in this study. NAC treatment comprised anthracycline alone, taxotere alone or sequential use of these two drugs. Survival curves have been established according to the Kaplan-Meier’s method. Comparison of curves were performed in using Log-rank test. The median of follow-up was 102 months (range 59 – 142 months) in October 2012. Results: Median age was 53.5 (range 34–78) years and median initial tumor size was 4cm (range 1-10). Objective response rate was 65% (86 patients), of which 8% (10 patients) had a complete response after 6 courses. One hundred and six (80%) underwent breast conservation surgery. Seven patients (5%) and ten patients achieved pCR (8%) according to Chevallier and Satatloff’s classification, respectively. Twenty patients did relapse and 18 patients died. At 10 years, Disease-free survival (DFS) and overall survival (OS) rate was 81% and 84%, respectively. All pCR patients, regardless of classification, did not relapse. However, the patients who achieved a pCR had not a significant difference in DFS and OS compared to the patients who did not. Conclusions: pCR was not a surrogate marker after a relatively short survey of 100 months for luminal breast cancers, who have generally late relapses. However, sixty five percent of patients had >50% reduction in primary tumor and 80% of patients had a breast conservation. Further studies are needed to identify new markers able to predict patients’ survival." @default.
• W2602247476 created "2017-04-07" @default.
• W2602247476 creator A5029086962 @default.
• W2602247476 creator A5030260555 @default.
• W2602247476 creator A5054491719 @default.
• W2602247476 creator A5057710694 @default.
• W2602247476 creator A5061340891 @default.
• W2602247476 creator A5062351916 @default.
• W2602247476 creator A5069540694 @default.
• W2602247476 creator A5077857574 @default.
• W2602247476 creator A5084368181 @default.
• W2602247476 creator A5088999457 @default.
• W2602247476 date "2013-05-20" @default.
• W2602247476 modified "2023-09-27" @default.
• W2602247476 title "Pathologic complete response (pCR) to predict patients’ survival in luminal breast cancer." @default.
• W2602247476 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.e11615" @default.
• W2602247476 hasPublicationYear "2013" @default.
• W2602247476 type Work @default.
• W2602247476 sameAs 2602247476 @default.
• W2602247476 citedByCount "0" @default.
• W2602247476 crossrefType "journal-article" @default.
• W2602247476 hasAuthorship W2602247476A5029086962 @default.
• W2602247476 hasAuthorship W2602247476A5030260555 @default.
• W2602247476 hasAuthorship W2602247476A5054491719 @default.
• W2602247476 hasAuthorship W2602247476A5057710694 @default.
• W2602247476 hasAuthorship W2602247476A5061340891 @default.
• W2602247476 hasAuthorship W2602247476A5062351916 @default.
• W2602247476 hasAuthorship W2602247476A5069540694 @default.
• W2602247476 hasAuthorship W2602247476A5077857574 @default.
• W2602247476 hasAuthorship W2602247476A5084368181 @default.
• W2602247476 hasAuthorship W2602247476A5088999457 @default.
• W2602247476 hasConcept C121608353 @default.
• W2602247476 hasConcept C126322002 @default.
• W2602247476 hasConcept C142724271 @default.
• W2602247476 hasConcept C143998085 @default.
• W2602247476 hasConcept C530470458 @default.
• W2602247476 hasConcept C71924100 @default.
• W2602247476 hasConceptScore W2602247476C121608353 @default.
• W2602247476 hasConceptScore W2602247476C126322002 @default.
• W2602247476 hasConceptScore W2602247476C142724271 @default.
• W2602247476 hasConceptScore W2602247476C143998085 @default.
• W2602247476 hasConceptScore W2602247476C530470458 @default.
• W2602247476 hasConceptScore W2602247476C71924100 @default.
• W2602247476 hasLocation W26022474761 @default.
• W2602247476 hasOpenAccess W2602247476 @default.
• W2602247476 hasPrimaryLocation W26022474761 @default.
• W2602247476 hasRelatedWork W1640963572 @default.
• W2602247476 hasRelatedWork W1976218272 @default.
• W2602247476 hasRelatedWork W2023281319 @default.
• W2602247476 hasRelatedWork W2064967649 @default.
• W2602247476 hasRelatedWork W2119967259 @default.
• W2602247476 hasRelatedWork W2139592878 @default.
• W2602247476 hasRelatedWork W2160211139 @default.
• W2602247476 hasRelatedWork W2297146073 @default.
• W2602247476 hasRelatedWork W2357452208 @default.
• W2602247476 hasRelatedWork W2415202772 @default.
• W2602247476 hasRelatedWork W2462067051 @default.
• W2602247476 hasRelatedWork W2790993522 @default.
• W2602247476 hasRelatedWork W2901007178 @default.
• W2602247476 hasRelatedWork W2969704016 @default.
• W2602247476 hasRelatedWork W2977330494 @default.
• W2602247476 hasRelatedWork W2995843417 @default.
• W2602247476 hasRelatedWork W3095269312 @default.
• W2602247476 hasRelatedWork W3097311565 @default.
• W2602247476 hasRelatedWork W3207999866 @default.
• W2602247476 hasRelatedWork W2843267922 @default.
• W2602247476 isParatext "false" @default.
• W2602247476 isRetracted "false" @default.
• W2602247476 magId "2602247476" @default.
• W2602247476 workType "article" @default.